A Phase 3 interventional study of faslodex 500mg and arimidex 1mg in Hormone Receptor Positive Breast Cancer, sponsored by AstraZeneca. Completed at 118 sites in 20 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.
A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg with Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 462 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women, fulfilling 1 of:
Exclusion Criteria:
Any of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets
Drug: faslodex 500mg · Drug: arimidex dummy
Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)
Drug: arimidex 1mg · Drug: faslodex dummy
2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
oral tablet 1 daily
2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
oral tablet 1 daily
Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole
PFS was defined as the time from randomisation until objective disease progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1), surgery or radiotherapy to manage worsening of disease or death by any cause (in the absence of progression). Outcome measure is reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.
Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)
Comparison of Overall Survival (OS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole; Percentage of Patients With Events
OS was defined as the time from randomisation until death by any cause. The current OS data correspond to that of the final analysis and the outcome measure is reported as percentage of patients with events.
Time frame: Baseline (Day 0) up to data cut-off for final analysis (up to approximately 116 months). Following disease progression, patients were to be contacted at 12 weekly intervals to determine survival status
Objective Response Rate (ORR) for Fulvestrant Treatment Versus Anastrozole Treatment
ORR was defined as the percentage patients with an objective response (i.e. those recording a partial response \[PR\] or complete response \[CR\]) at some point during the study, prior to disease progression. ORR was assessed in patients with measurable disease at baseline only. The determination of measurable disease at baseline was done using baseline RECIST data. CR was disappearance of all target lesions since baseline; was any pathological lymph nodes selected as target lesions (TL) to have a reduction in short axis to \<10 millimeter. PR was at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Duration of Response (DoR) for Fulvestrant Treatment Versus Anastrozole Treatment
DoR was defined only for patients who had an objective response, as the time in days from date of first documentation of response (CR/PR) until date of disease progression. CR was disappearance of all target lesions since baseline; any pathological lymph nodes selected as TL to have a reduction in short axis to \<10 mm. At least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Expected Duration of Response (EDoR) for Fulvestrant Treatment Versus Anastrozole Treatment
EDoR was estimated using the formula EDoR = p Efp(x), where x = DoR, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65).
Time frame: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Clinical Benefit Rate (CBR) for Fulvestrant Treatment Versus Anastrozole Treatment
CBR was defined as the percentage of patients who had a clinical benefit (i.e. best objective response of CR, PR or stable disease), that was maintained for at least 24 weeks, prior to any evidence of progression. Note that a minimum duration of 22 weeks for CBR was applicable in the analysis (rather than 24 weeks) to allow for the protocolled window of +/-2 weeks.
Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Duration of Clinical Benefit (DoCB) for Fulvestrant Treatment Versus Anastrozole Treatment
DoCB was defined only for patients who had clinical benefit, as the time in days from date of randomisation until the date of disease progression.
Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Expected Duration of Clinical Benefit (EDoCB) for Fulvestrant Treatment Versus Anastrozole Treatment
EDoCB was estimated using the formula EDoCB = p Efp(x), where x = EDoCB, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65).
Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Comparison of the Effect of Fulvestrant Treatment Versus Anastrozole Treatment on Time to Deterioration of Health-Related Quality of Life (HRQoL)
The Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire was the instrument selected to assess HRQoL and comprised of following subscales: physical well-being (PWB), functional well-being (FWB), social well-being, emotional well-being, and breast cancer subscale (BCS). The main outcome measure from the FACT-B questionnaire was the Trial Outcome Index (TOI), which was a summary of the following subscales: PWB, FWB, and BCS. Outcome measure is reported as median time to deterioration, defined as the interval from the date of baseline of final analysis to the first assessment of worsened without an improvement in the next 12 weeks in FACT-B TOI, or the date of death (by any cause in the absence of symptom deterioration). Time to deterioration as measured by FACT-B total score was derived similarly and is also reported.
Time frame: Quality of life questionnaires administered at 3 months post objective disease progression, then at 6-monthly intervals (approximately 75 months)
First patient enrolled: 17 October 2012.
| Milestone | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Started | 230 | 232 |
| Completed | 25 | 31 |
| Not completed | 205 | 201 |
| Withdrew: Death | 147 | 145 |
| Withdrew: Withdrawal by subject | 39 | 41 |
| Withdrew: Lost to follow-up | 15 | 12 |
| Withdrew: Eligibility criteria not fulfilled | 2 | 3 |
| Withdrew: Other | 2 | 0 |
PFS was defined as the time from randomisation until objective disease progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1), surgery or radiotherapy to manage worsening of disease or death by any cause (in the absence of progression). Outcome measure is reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.
| Months | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole | 16.6 (13.83 to 20.99) | 13.8 (11.99 to 16.59) |
OS was defined as the time from randomisation until death by any cause. The current OS data correspond to that of the final analysis and the outcome measure is reported as percentage of patients with events.
| Percentage of patients | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Comparison of Overall Survival (OS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole; Percentage of Patients With Events | 68.3 | 67.7 |
ORR was defined as the percentage patients with an objective response (i.e. those recording a partial response \[PR\] or complete response \[CR\]) at some point during the study, prior to disease progression. ORR was assessed in patients with measurable disease at baseline only. The determination of measurable disease at baseline was done using baseline RECIST data. CR was disappearance of all target lesions since baseline; was any pathological lymph nodes selected as target lesions (TL) to have a reduction in short axis to \<10 millimeter. PR was at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
| Percentage of participants | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Objective Response Rate (ORR) for Fulvestrant Treatment Versus Anastrozole Treatment | 46.1 | 44.9 |
DoR was defined only for patients who had an objective response, as the time in days from date of first documentation of response (CR/PR) until date of disease progression. CR was disappearance of all target lesions since baseline; any pathological lymph nodes selected as TL to have a reduction in short axis to \<10 mm. At least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
| Months | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Duration of Response (DoR) for Fulvestrant Treatment Versus Anastrozole Treatment | 20.0 (10.6 to NA) | 13.2 (8.3 to 24.7) |
EDoR was estimated using the formula EDoR = p Efp(x), where x = DoR, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65).
| Days | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Expected Duration of Response (EDoR) for Fulvestrant Treatment Versus Anastrozole Treatment | 346.84 | 227.58 |
CBR was defined as the percentage of patients who had a clinical benefit (i.e. best objective response of CR, PR or stable disease), that was maintained for at least 24 weeks, prior to any evidence of progression. Note that a minimum duration of 22 weeks for CBR was applicable in the analysis (rather than 24 weeks) to allow for the protocolled window of +/-2 weeks.
| Percentage of participants | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Clinical Benefit Rate (CBR) for Fulvestrant Treatment Versus Anastrozole Treatment | 78.3 | 74.1 |
DoCB was defined only for patients who had clinical benefit, as the time in days from date of randomisation until the date of disease progression.
| Months | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Duration of Clinical Benefit (DoCB) for Fulvestrant Treatment Versus Anastrozole Treatment | 22.1 (11.2 to NA) | 19.1 (11.3 to 30.4) |
EDoCB was estimated using the formula EDoCB = p Efp(x), where x = EDoCB, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65).
| Days | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Expected Duration of Clinical Benefit (EDoCB) for Fulvestrant Treatment Versus Anastrozole Treatment | 667.94 | 532.04 |
The Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire was the instrument selected to assess HRQoL and comprised of following subscales: physical well-being (PWB), functional well-being (FWB), social well-being, emotional well-being, and breast cancer subscale (BCS). The main outcome measure from the FACT-B questionnaire was the Trial Outcome Index (TOI), which was a summary of the following subscales: PWB, FWB, and BCS. Outcome measure is reported as median time to deterioration, defined as the interval from the date of baseline of final analysis to the first assessment of worsened without an improvement in the next 12 weeks in FACT-B TOI, or the date of death (by any cause in the absence of symptom deterioration). Time to deterioration as measured by FACT-B total score was derived similarly and is also reported.
| months | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Time to TOI deterioration | 14.1 (5.5 to 44.1) | 11.1 (5.5 to 38.3) |
| Time to FACT-B total score deterioration | 13.8 (5.5 to 38.7) | 11.1 (4.8 to 33.6) |
Collected over 116 months (duration from first patient enrolled to data cut-off for the final analysis). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant 500 mg | 157/230 (68.3%) | 39/228 (17.1%) | 125/228 (54.8%) |
| Anastrozole 1 mg | 159/232 (68.5%) | 36/232 (15.5%) | 127/232 (54.7%) |
| Event | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 7/228 | 2/232 |
| PneumoniaInfections and infestations | 3/228 | 4/232 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/228 | 1/232 |
| Cardiac failureCardiac disorders | 0/228 | 3/232 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/228 | 3/232 |
| PeritonitisInfections and infestations | 2/228 | 0/232 |
| Urinary tract infectionInfections and infestations | 2/228 | 0/232 |
| Radius fractureInjury, poisoning and procedural complications | 2/228 | 0/232 |
| Cerebrovascular accidentNervous system disorders | 2/228 | 0/232 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/228 | 0/232 |
| Event | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 42/228 | 31/232 |
| FatigueGeneral disorders | 29/228 | 18/232 |
| Hot flushVascular disorders | 26/228 | 24/232 |
| NauseaGastrointestinal disorders | 25/228 | 25/232 |
| Back painMusculoskeletal and connective tissue disorders | 22/228 | 18/232 |
| HypertensionVascular disorders | 18/228 | 22/232 |
| AnaemiaBlood and lymphatic system disorders | 9/228 | 20/232 |
| InsomniaPsychiatric disorders | 18/228 | 15/232 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 17/228 | 11/232 |
| Alanine aminotransferase increasedInvestigations | 16/228 | 8/232 |
The intention to treat (ITT) analysis set included all randomised patients.
| Age, Continuous(years) | Fulvestrant 500 mg | Anastrozole 1 mg | Total |
|---|---|---|---|
| Mean | 63.8 ± 9.86 | 63.3 ± 10.38 | 63.5 ± 10.12 |
| Sex: Female, Male(Participants) | Fulvestrant 500 mg | Anastrozole 1 mg | Total |
|---|---|---|---|
| Female | 230 | 232 | 462 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Fulvestrant 500 mg | Anastrozole 1 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 5 | 6 |
| Asian | 36 | 34 | 70 |
| Black or African American | 4 | 4 | 8 |
| White | 175 | 174 | 349 |
| Other | 14 | 15 | 29 |
Showing the first 100 of 118 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2012 to primary completion in Apr 2016, 41 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 41 months is close to that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant